REGULATION OF NATIONAL GENOME EDITING POLICIES: LEGAL FRAMEWORK AND JUDICIAL PRECEDENTS

1. INTRODUCTION

National genome editing policies establish the legal, scientific, and ethical framework for modifying genetic material in plants, animals, microorganisms, and human cells. Technologies such as CRISPR-Cas enable targeted genetic changes with applications in agriculture, biotechnology, disease treatment, and scientific research.

Although genome editing offers opportunities for disease prevention, crop improvement, and scientific innovation, it also raises concerns regarding unintended genetic changes, ecological disruption, human dignity, genetic privacy, and intergenerational consequences. National policies must therefore balance research freedom with biosafety, ethical oversight, public accountability, and protection against irreversible harm.

2. LEGAL AND REGULATORY FRAMEWORK IN INDIA

A. ENVIRONMENT (PROTECTION) ACT, 1986

The Environment (Protection) Act, 1986, provides the statutory foundation for regulating genetically engineered organisms through the Rules of 1989 concerning hazardous microorganisms and genetically engineered organisms or cells. Regulatory bodies include Institutional Biosafety Committees (IBSCs), the Review Committee on Genetic Manipulation (RCGM), and the Genetic Engineering Appraisal Committee (GEAC), according to their respective jurisdictions.

B. GENOME-EDITED PLANTS

The Department of Biotechnology's Guidelines for the Safety Assessment of Genome Edited Plants, 2022, establish a framework for assessing relevant genome-edited plant categories. Qualifying SDN-1 and SDN-2 plants that contain no exogenously introduced DNA are exempted from Rules 7–11 of the 1989 Rules under the Ministry's March 2022 notification. This exemption does not amount to blanket permission for commercial release or remove other applicable agricultural, environmental, or food-safety requirements.

C. HUMAN GENOME EDITING

Human gene-editing research must comply with applicable biomedical research ethics requirements, the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, and relevant Department of Biotechnology and Indian Council of Medical Research guidelines. Investigational gene therapies require applicable regulatory approvals, ethics review, informed consent, and safety monitoring.

D. CONSTITUTIONAL AND INTERNATIONAL PRINCIPLES

Articles 14 and 21 of the Constitution provide safeguards against arbitrary State action and protect life and personal liberty. The Convention on Biological Diversity and the Cartagena Protocol on Biosafety are relevant to biodiversity protection and transboundary movement of living modified organisms, subject to their scope and India's treaty obligations.

3. CORE PRINCIPLES OF NATIONAL GENOME EDITING POLICY

A. PRECAUTIONARY PRINCIPLE: Research and environmental release should be informed by appropriate risk assessment, especially where adverse effects could be serious or irreversible.

B. ETHICAL OVERSIGHT: Human genome-editing research must respect autonomy, informed consent, dignity, and independent ethics review. Heritable human genome editing raises additional intergenerational and ethical concerns.

C. TRANSPARENCY: Regulatory decisions should disclose relevant scientific evidence, assessment procedures, and conflicts of interest, subject to legitimate confidentiality protections.

D. BIOSAFETY AND MONITORING: Policies should address unintended genetic effects, gene flow, ecological consequences, containment, traceability, and post-release monitoring where appropriate.

E. PUBLIC PARTICIPATION: Farmers, patients, researchers, State Governments, affected communities, and independent experts should have meaningful opportunities to contribute to policy development.

4. IMPORTANT CASE LAWS

1. Gene Campaign v. Union of India, 2024 INSC 545 — Direct authority.

The Supreme Court considered challenges concerning genetically modified mustard, DMH-11. The judges disagreed on the validity of the environmental release approval, so the approval issue was not conclusively resolved by a majority in that judgment. However, the Court directed the Union Government to develop a national policy on GM crops through stakeholder consultation and emphasised the importance of scrutiny of expert credentials and conflicts of interest. The directions are particularly relevant to national biotechnology policy.

2. Vellore Citizens' Welfare Forum v. Union of India, (1996) 5 SCC 647 — Direct authority on environmental principles.

The Supreme Court recognised the precautionary principle and polluter pays principle as essential features of sustainable development. These principles support preventive assessment and accountability when genome-edited organisms may create environmental risks.

3. A.P. Pollution Control Board v. Prof. M.V. Nayudu, (1999) 2 SCC 718 — Direct authority on scientific uncertainty.

The Supreme Court emphasised scientific expertise and precaution in environmental decision-making. Its reasoning supports independent, technically sound risk assessment before approving potentially hazardous biological interventions.

4. M.C. Mehta v. Kamal Nath, (1997) 1 SCC 388 — Analogous authority.

The Supreme Court applied the public trust doctrine to the protection of natural resources. The doctrine is relevant when genome-editing activities threaten biodiversity or ecological resources held for public benefit.

5. N.D. Jayal v. Union of India, (2004) 9 SCC 362 — Analogous authority.

The Court discussed sustainable development and the relationship between development objectives and environmental protection. Its reasoning supports genome-editing policies that evaluate scientific benefits alongside ecological and public-health consequences.

6. Monsanto Technology LLC v. Nuziveedu Seeds Ltd., (2019) 3 SCC 381 — Analogous authority.

The Supreme Court considered patent-related disputes concerning genetically modified cotton technology. The case illustrates the distinction between intellectual property rights and regulatory permission to commercialise biotechnology products. Patent protection alone does not establish biosafety or authorise environmental release.

5. PRACTICAL COMPLIANCE REQUIREMENTS

National authorities should establish clear approval pathways for different genome-editing applications, require scientifically justified risk assessments, maintain transparent regulatory records, and monitor compliance with biosafety conditions. Developers should document editing methods, genetic characterisation, relevant safety findings, and any unintended effects.

Human applications require additional safeguards concerning consent, clinical evidence, privacy, and long-term follow-up. Environmental applications should consider biodiversity, gene flow, and local ecological conditions. Regulatory frameworks should also provide mechanisms for reporting adverse events, investigating violations, and imposing proportionate corrective measures.

6. CONCLUSION

National genome-editing policies are essential to ensure that biotechnology advances within a framework of safety, accountability, and ethical responsibility. India's existing framework combines environmental legislation, biosafety rules, technical guidelines, clinical research regulation, and constitutional principles. Judicial decisions reinforce precaution, scientific scrutiny, and transparent governance, although no single judgment creates a comprehensive genome-editing code. A coherent national policy should provide clear regulatory pathways while protecting human rights, public health, biodiversity, and legitimate scientific innovation.